Replimune Shares Soar After Advisory Panel Backs IGNYTE Data
Replimune stock jumped 125.3% in pre-market trading after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted 10 to 3 in favor of the efficacy data from the company's IGNYTE trial of RP1 (vusolimogene oderparepvec) combined with nivolumab for advanced melanoma patients who progressed on prior anti-PD-1 therapy. The panel found t…